Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
NCT00704288
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
222
Enrollment
INDUSTRY
Sponsor class
Conditions
Glioblastoma Multiforme
Interventions
DRUG:
XL184
Sponsor
Exelixis